^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    daunorubicin

    i
    Other names: FI-6339, RP-13057
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor, DNA intercalator
    Related drugs:
    2d
    MM1YA-A04: Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=162, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2028 --> Nov 2027 | Initiation date: Nov 2025 --> Feb 2026 | Trial primary completion date: Jul 2028 --> Nov 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)
    2d
    A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, University of Washington | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    ENG (Endoglin)
    |
    cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)
    3d
    Vitexin induces apoptosis and enhances daunorubicin efficacy in acute leukemia via modulation of the HIF-1α/Bcl-2/caspase-3 pathway. (PubMed, Sci Rep)
    Vitexin induces apoptosis via modulation of HIF-1α/Bcl-2/caspase-3 pathway and potentiates efficacy of daunorubicin, thereby supporting potential as an adjunctive therapeutic in acute leukemia. Further in vivo studies are necessary to elucidate pharmacokinetics and clinical applicability.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CASP3 (Caspase 3) • ANXA5 (Annexin A5)
    |
    daunorubicin
    4d
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    8d
    A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=70, Suspended, St. Jude Children's Research Hospital | Recruiting --> Suspended
    Trial suspension
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV
    10d
    Phenazine 5,10-dioxide analogues as potential therapeutics in AML: Efficacy on patient-derived blasts, in zebrafish larvae xenografts and synergy with venetoclax. (PubMed, Transl Oncol)
    The phenazine 5,10-dioxides cytotoxicity towards primary blasts correlated with the blast's sensitivity to daunorubicin, presumably due to similar mode of action towards AML cells. Additionally, synergism with the AML drug venetoclax (VTX) was found in the AML cell lines MOLM-13 and MV4-11. The efficacy of phenazine 5,10-dioxides towards primary AML blasts, synergism with VTX and low toxicity in effective concentrations in zebrafish larva AML xenografts suggests potential for these compounds in future AML therapy for patients unfit for intensive chemotherapy.
    Journal
    |
    CD34 (CD34 molecule)
    |
    Venclexta (venetoclax) • daunorubicin
    13d
    Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients (clinicaltrials.gov)
    P2, N=20, Terminated, Institute of Hematology & Blood Diseases Hospital, China | N=40 --> 20 | Recruiting --> Terminated; The research center has conducted a more comprehensive study.
    Enrollment change • Trial termination • Minimal residual disease
    |
    NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • NUP214 (Nucleoporin 214) • DEK (DEK Proto-Oncogene)
    |
    NPM1 mutation
    |
    Venclexta (venetoclax) • azacitidine • daunorubicin
    16d
    A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2/3, N=80, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P2/3 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • BL-M11D1
    19d
    CHARACTERISTIC OF MYELOID SARCOMA BY CANCER GENOME PROFILING AND ALGORITHM OF POTENTIAL BIOMARKERS FOR UTERINE MESENCHYMAL TUMOR. (PubMed, Georgian Med News)
    In cancer treatment, contrast-enhanced MRI is useful for identifying the size and location of tumor masses. However, contrast-enhanced MRI does not lead to the diagnosis of tumor masses. Therefore, early blood tests and tumor biopsy results are important for differential diagnosis and early treatment decisions.
    Journal
    |
    IL2 (Interleukin 2)
    |
    daunorubicin
    22d
    Tirabrutinib-anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance. (PubMed, Expert Opin Drug Metab Toxicol)
    Our in vitro data demonstrate that tirabrutinib influences daunorubicin pharmacodynamics by targeting both metabolic and transport pathways. However, Chou - Talalay analysis highlights the importance of appropriate dosing to achieve therapeutic synergy in combination regimens.
    Journal
    |
    AKR1C3 (Aldo-Keto Reductase Family 1 Member C3)
    |
    daunorubicin • Velexbru (tirabrutinib)
    24d
    Investigating of harmane, harmine, and norharman as inhibitors of MDR1 and MRP1 to overcome chemotherapy resistance in cancer cells. (PubMed, Sci Rep)
    In conclusion, these alkaloids enhanced the sensitivity of EPG85.257RDB and A2780 cells to daunorubicin, likely through inhibition of drug efflux activity. These findings highlight β-carboline alkaloids as promising candidates for combination therapy in overcoming multidrug resistance in cancer.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    daunorubicin
    30d
    AML-DS-2025: The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia (clinicaltrials.gov)
    P3, N=100, Recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology
    New P3 trial
    |
    GATA1 (GATA Binding Protein 1)
    |
    cytarabine • etoposide IV • daunorubicin • idarubicin hydrochloride